Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes:Action LADA 12 by Achenbach, Peter et al.
                          Achenbach, P., Hawa, M. I., Krause, S., Lampasona, V., Jerram, S. T.,
Williams, A. J. K., ... Action LADA consortium (2018). Autoantibodies to N-
terminally truncated GAD improve clinical phenotyping of individuals with
adult-onset diabetes: Action LADA 12. Diabetologia, 61(7), 1644-1649.
https://doi.org/10.1007/s00125-018-4605-3
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1007/s00125-018-4605-3
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Springer at
https://link.springer.com/article/10.1007%2Fs00125-018-4605-3 . Please refer to any applicable terms of use of
the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
SHORT COMMUNICATION
Autoantibodies to N-terminally truncated GAD improve clinical
phenotyping of individuals with adult-onset diabetes: Action LADA 12
Peter Achenbach1,2,3,4 & Mohammed I. Hawa5 & Stephanie Krause1,2 & Vito Lampasona6 & Samuel T. Jerram5 &
Alistair J. K. Williams7 & Ezio Bonifacio4,8,9 & Anette G. Ziegler1,2,3,4 & R. David Leslie5 & on behalf of the Action LADA
consortium
Received: 30 December 2017 /Accepted: 8 March 2018 /Published online: 4 April 2018
# The Author(s) 2018
Abstract
Aims/hypothesis Adult-onset type 1 diabetes, in which the 65 kDa isoform of GAD (GAD65) is a major autoantigen, has a broad
clinical phenotype encompassing variable need for insulin therapy. This study aimed to evaluate whether autoantibodies against
N-terminally truncated GAD65 more closely defined a type 1 diabetes phenotype associated with insulin therapy.
Methods Of 1114 participants with adult-onset diabetes from the Action LADA (latent autoimmune diabetes in adults) study
with sufficient sera, we selected those designated type 1 (n = 511) or type 2 diabetes (n = 603) and retested the samples in
radiobinding assays for human full-length GAD65 autoantibodies (f-GADA) and N-terminally truncated (amino acids 96–
585) GAD65 autoantibodies (t-GADA). Individuals’ clinical phenotypes were analysed according to antibody binding patterns.
Results Overall, 478 individuals were f-GADA-positive, 431 were t-GADA-positive and 628 were negative in both assays. Risk
of insulin treatment was augmented in t-GADA-positive individuals (OR 4.69 [95% CI 3.57, 6.17]) compared with f-GADA-
positive individuals (OR 3.86 [95% CI 2.95, 5.06]), irrespective of diabetes duration. Of 55 individuals who were f-GADA-
positive but t-GADA-negative, i.e. with antibody binding restricted to the N-terminus of GAD65, the phenotype was similar to
type 2 diabetes with low risk of progression to insulin treatment. Compared with these individuals with N-terminal GAD65-
restricted GADA, t-GADA-positive individuals were younger at diagnosis (p = 0.005), leaner (p < 0.0001) and more often had
multiple diabetes-associated autoantibodies (28.3% vs 7.3%; p = 0.0005).
Conclusions/interpretation In individuals with adult-onset diabetes, presence of N-terminally truncated GAD65 autoantibodies
is associated with the clinical phenotype of autoimmune type 1 diabetes and predicts insulin therapy.
A list of members of the Action LADA consortium is available in the
Appendix.
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Abbreviations
aa Amino acids
GAD65 65 kDa isoform of GAD
GADA GAD autoantibodies
f-GADA Full-length (aa 1–585) GAD65 autoantibodies
t-GADA N-terminally truncated (aa 96–585)
GAD65 autoantibodies
IA-2A Insulinoma-associated antigen-2 autoantibodies
IQR Interquartile range
LADA Latent autoimmune diabetes in adults
NIDDK National Institute of Diabetes and Digestive
and Kidney diseases
ZnT8A Zinc transporter-8 autoantibodies
Introduction
Type 1 diabetes can occur at any age and is of variable sever-
ity. In adults presenting with the disease, unlike children, it
may masquerade as type 2 diabetes, since insulin therapy is
not always required [1]. Established autoimmune markers of
type 1 diabetes, notably GAD autoantibodies (GADA), have
been used to screen individuals presenting with adult-onset
diabetes to identify those with type 1 diabetes, including the
so-called latent autoimmune diabetes in adults (LADA) [2, 3].
Identifying individuals with adult-onset type 1 diabetes is im-
portant as, compared with people with type 2 diabetes, they
have a different clinical course and different comorbidities [1].
In adult-onset diabetes, the detection of GADA together with
insulinoma-associated antigen-2 autoantibodies (IA-2A) or
zinc transporter-8 autoantibodies (ZnT8A) is highly predictive
of the need for insulin therapy [4]. Nevertheless, the majority
of antibody-positive individuals with adult-onset diabetes
present with GADA alone, which may represent either false-
positive antibody assay signals in an adult population with a
relatively low prevalence of autoimmune type 1 diabetes, or
true-positive autoantibodies with high risk for progression to
insulin therapy. Antibody characteristics might facilitate diag-
nosis and estimation of risk for disease progression because
high-affinity GADA responses against the middle (amino
acids [aa] 235–444) and C-terminal (aa 445–585) domains
of the 65 kDa isoform of GAD (GAD65) were associated with
type 1 diabetes development in children and adolescents [5];
and high antibody titre [6] and binding to C-terminal (aa 437-
585) GAD65-depending epitopes were reported as character-
istic features of LADA individuals [7]. In contrast, low-
•
•
•
•
•
•
•
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affinity GADA and/or antibody responses restricted to the N-
terminal (aa 1–95) domain of GAD65 were not associated
with classic type 1 diabetes [5, 8]. Furthermore, using N-
terminally truncated (aa 96–585) GAD65 antigen in GADA
radiobinding assays improved the specificity for type 1 diabe-
tes [9]. The aim of this study was to evaluate N-terminally
truncated (aa 96–585) GAD65 autoantibodies (t-GADA),
compared with full-length GAD65 autoantibodies (f-
GADA), in a large cohort of adult-onset diabetes individuals
with variable clinical phenotype.
Methods
Individuals and samples Sera were obtained from individuals
with adult-onset diabetes participating in the Action LADA
study [3]. The study design is cross-sectional and includes
individuals with adult-onset diabetes (originally n = 6156;
aged 30–70 years; diabetes diagnosed within 5 years) with
the aim of identifying risk factors for adult-onset autoimmune
diabetes (www.actionlada.org). The study protocol is in
accordance with the Declaration of Helsinki and was
approved by local ethics committees. Informed written
consent was obtained from all individuals before blood
sampling. The study was approved by the UK National
Research Ethics Committee (no. P/02/240).
All samples had previously been tested for GADA, IA-2A
and ZnT8A in the central laboratory in London [3]. For the
current study, we selected two groups from our initial cohort:
of those with sufficient sera in storage, 511 individuals with
beta cell autoantibodies (all GADA-positive), and 603 indi-
viduals without beta cell autoantibodies of similar age and
diabetes duration (Table 1). Of these 1114 participants, the
median age at diagnosis was 48.2 years (interquartile range
[IQR] 39.5–56.3 years) and median disease duration at sample
collection was 2.0 years (IQR 0.6–3.5 years); while informa-
tion on diabetes treatment and BMI was available for 1045
(94%) and 1059 (95%) individuals, respectively.
Antibody measurements Sera of the 1114 participants were
retested for GADA in the Munich laboratory using the
National Institute of Diabetes and Digestive and Kidney dis-
eases (NIDDK) harmonised radiobinding assay [10]. In vitro
transcribed/translated and [35S]-labelled human full-length (aa
1–585) GAD65 and N-terminally truncated (aa 96–585)
GAD65 (cloned by Vito Lampasona, San Raffaele Institute,
Milan, Italy) were used as antigens to detect f-GADA and t-
GADA, respectively. The assays achieved adjusted sensitivi-
ties of 64% (f-GADA) and 72% (t-GADA) at 95% specificity
in the 2012 Islet Autoantibody Standardization Program
workshop [9]. Throughout all measurements, investigators
were blinded with respect to the previously determined auto-
antibody status of the samples.
Statistical analysisWe used the Mann–WhitneyU test to com-
pare continuous variables, Fisher’s exact test to compare fre-
quencies and Spearman correlation to determine the correla-
tion between antibody titres. Data are presented, where appro-
priate, as medians with IQRs or ORs with 95% CIs. For all
analyses, a two-tailed p value of <0.05 was considered signif-
icant. Statistical analyses were performed using the GraphPad
Prism 3 program (GraphPad Software, La Jolla, CA, USA).
Results
Of 1114 participants with adult-onset diabetes, 478 were f-
GADA-positive using the NIDDK harmonised radiobinding
assay. Of these 478 f-GADA-positive individuals, 55 (11.5%)
were t-GADA-negative, thus demonstrating antibody binding
restricted to N-terminal GAD65 epitopes (Fig. 1a). Such re-
stricted responses were seen in four (3.2%) of the 126 f-
GADA-positive individuals who also had IA-2A and/or
ZnT8A (electronic supplementary material [ESM] Fig. 1a),
in contrast to 51 (14.5%) of the 352 individuals who only
had f-GADA positivity (ESM Fig. 1b; p = 0.0003). Overall,
431 individuals were t-GADA-positive. Antibody titres were
strongly correlated between f-GADA and t-GADA assays
(r = 0.86, p < 0.0001).
For clinical phenotype, f-GADA-positive individuals were
diagnosed with diabetes at a median age of 47.0 years (IQR
38.4–55.7 years), median BMI of 25.6 kg/m2 (IQR 22.8–
29.4 kg/m2) and 51.2% required insulin therapy (Table 1).
For the t-GADA-positive individuals, median age at diagnosis
was 46.6 years (IQR 38.0–55.5 years), median BMI 24.9 kg/
m2 (IQR 22.6–28.8 kg/m2) and 55.3% were on insulin thera-
py. For the whole cohort, risk of insulin treatment was aug-
mented in t-GADA-positive individuals (OR 4.69 [95% CI
3.57, 6.17]; p < 0.0001 vs t-GADA-negative) compared with
f-GADA-positive individuals (OR 3.86 [95% CI 2.95, 5.06];
p < 0.0001 vs f-GADA-negative). This difference was evident
irrespective of the disease duration: both for the cohorts
assessed at 1 month post-diagnosis (OR 5.20 [95% CI 3.89,
6.94] and 4.42 [3.32, 5.88], respectively) and at 6 months
post-diagnosis (OR 4.92 [95% CI 3.61, 6.69] and 4.25 [95%
CI 3.13, 5.77], respectively).
Strikingly, when comparing the t-GADA-positive individ-
uals with individuals who were N-terminal GAD65-restricted
in antibody binding, i.e. f-GADA-positive but t-GADA-nega-
tive, the latter required insulin treatment less often (13.7%;
p < 0.0001; Fig. 1b), were older at diagnosis (median age
52.0 years [IQR 41.8–59.8 years]; p = 0.005; Fig. 1c) and were
more obese (median BMI 29.9 kg/m2 [IQR 26.7–35.9 kg/m2];
p < 0.0001; Fig. 1d). Moreover, individuals with N-terminal
GAD65-restricted antibodies were not phenotypically different
from individuals who were negative for both f-GADA and t-
GADA, i.e. type 2 diabetes individuals (Fig. 1, Table 1).
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Finally, when comparing the individuals who were positive
(n = 423) or negative (n = 628) in both assays (f-GADA and t-
GADA), these positive individuals were younger at diagnosis
(p = 0.003), leaner (p < 0.0001) and were more often on insu-
lin treatment (p < 0.0001) (Table 1).
Discussion
In this study, we found that overall, f-GADA-positive partic-
ipants and t-GADA-positive participants with adult-onset dia-
betes had a similar clinical phenotype that distinguished them
from GADA-negative participants with type 2 diabetes.
Importantly, however, a subgroup of individuals who were
positive for f-GADA but negative for t-GADA (i.e. individ-
uals with N-terminal GAD65-restricted GADA) had a similar
clinical phenotype to GADA-negative, type 2 diabetic indi-
viduals, albeit in relatively low numbers. It is therefore possi-
ble that the N-terminal GAD65-restricted GADA, as pro-
posed, does not detect individuals with autoimmune type 1
diabetes, at least using clinical phenotype as a proxy, whilst
screening for t-GADA could be helpful for clinical assessment
and prediction of insulin therapy.
Screening adult-onset diabetes individuals for GADA to
identify autoimmune type 1 diabetes is limited by false-
positive and false-negative assay results [1]. Using the t-
GADA assay, when compared with the f-GADA assay, we
identified a reduced number of GADA-positive individuals
(88%) and confirmed a high number (99%) of GADA-
negative individuals. Further, we found that the risk of being
on insulin treatment within 5 years from diagnosis when pos-
itive for t-GADAwas higher (OR 4.69) than in those individ-
uals positive for f-GADA (OR 3.86). Those positive for t-
GADA, compared with those with N-terminal GAD65-re-
stricted GADA, were enriched for phenotypic features char-
acteristic of individuals with adult-onset type 1 diabetes, in-
cluding being younger, leaner and with an increased need for
insulin treatment.
Differences in GADA epitope binding between LADA in-
dividuals with clinical characteristics similar to either type 1 or
type 2 diabetes have previously been reported [7]. Individuals
with antibodies against epitopes within the N-terminal/middle
(aa 1–360) GAD65 region and negative for antibodies against
the C-terminal (aa 437–585) GAD65 region showed clinical
features that were indistinguishable from those of GADA-
negative individuals, whereas the presence of autoantibodies
directed to both GAD65 regions identified a subgroup of in-
dividuals with low BMI, low basal C-peptide values and the
need for insulin treatment [7]. In contrast to this former study
and based on our previous data [5, 9], we used the N-
terminally truncated (aa 96–585) GAD65 antigen for our t-
GADA assay, containing epitopes within the middle and C-
terminal GAD65 regions. We believe that the false-positive
rate in screening tests can likely be decreased by using this
t-GADA assay to identify those at risk of progression to insu-
lin treatment.
In conclusion, our findings suggest that in individuals with
adult-onset diabetes, screening for t-GADA augments the
clinical phenotype of autoimmune type 1 diabetes. This may
have important practical implications given the relatively large
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GADA epitope reactivity and
clinical phenotype. In (a), levels
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number of adult patients who are screened for GADA, both
for diabetes classification and prediction of risk for insulin
therapy.
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